021-51111890
购物车（）
sales@molnova.cn
Adomeglivant
CAS No. 1488363-78-5
Adomeglivant ( LY-2409021 )
产品货号. M12058 CAS No. 1488363-78-5
一种有效的、选择性的、口服活性的人胰高血糖素受体小分子拮抗剂，Ki 为 6.66 nM。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ￥708 | 有现货 |
|
| 10MG | ￥1169 | 有现货 |
|
| 25MG | ￥1841 | 有现货 |
|
| 50MG | ￥3469 | 有现货 |
|
| 100MG | ￥4788 | 有现货 |
|
| 200MG | ￥6552 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
| 1 mL x 10 mM in DMSO | ￥847 | 有现货 |
|
生物学信息
-
产品名称Adomeglivant
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述一种有效的、选择性的、口服活性的人胰高血糖素受体小分子拮抗剂，Ki 为 6.66 nM。
-
产品描述A potent, selective, orally active, small-molecule antagonist of human glucagon receptor with Ki of 6.66 nM; displays >200-fold selectivity over related receptors; exhibits robust glucose-lowering in response to daily oral administration in an ob/ob mouse model of type 2 diabetes mellitus.Diabetes Phase 2 Discontinued.
-
体外实验——
-
体内实验Animal Model:Avpires-Cre+ miceDosage:5 mg/kg Administration:Intraperitoneal injection, 30 minutes prior to CNOResult:Completely abolished the hyperglycaemic action of CNO.
-
同义词LY-2409021
-
通路GPCR/G Protein
-
靶点Glucagon Receptor
-
受体Glucagon Receptor
-
研究领域Metabolic Disease
-
适应症Diabetes
化学信息
-
CAS Number1488363-78-5
-
分子量555.6277
-
分子式C32H36F3NO4
-
纯度>98% (HPLC)
-
溶解度DMSO: ≥ 5.3 mg/mL
-
SMILESO=C(O)CCNC(C1=CC=C([C@@H](OC2=CC(C)=C(C3=CC=C(C(C)(C)C)C=C3)C(C)=C2)CCC(F)(F)F)C=C1)=O
-
化学全称β-Alanine, N-[4-[(1S)-1-[[4'-(1,1-dimethylethyl)-2,6-dimethyl[1,1'-biphenyl]-4-yl]oxy]-4,4,4-trifluorobutyl]benzoyl]-
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Kelly RP, et al. Diabetes Obes Metab. 2015 Apr;17(4):414-22.
2. Grover S, et al. BMC Bioinformatics. 2014;15 Suppl 16:S13.
3. Kazda CM, et al. Diabetes Obes Metab. 2017 Aug;19(8):1071-1077.
产品手册
关联产品
-
GLP-1(7-36) Acetate
GLP-1(7-36) Acetate is a major intestinal hormone that stimulates glucose-induced insulin secretion from β cells.
-
des-His1-[Glu9]-Gluc...
Glucagon receptor antagonist (pA2 = 7.2 for inhibition of glucagon-induced adenylyl cyclase activation in rat liver membranes); displays no agonist activity. Enhances glucose-stimulated pancreatic insulin release in vitro. Blocks added glucagon-induced hyperglycemia in normal rabbits without affecting glycogenolysis in vivo. Also blocks endogenous glucagon-induced hyperglycemia in streptozocin diabetic rats.
-
GLP-1(7-37)
GLP-1 (7-37) is a truncated, bioactive form of GLP-1 that is the product of proglucagon processing in intestinal endocrine L cells.
